<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844336</url>
  </required_header>
  <id_info>
    <org_study_id>PR003</org_study_id>
    <nct_id>NCT01844336</nct_id>
  </id_info>
  <brief_title>PBASE System Idiopathic Rhinitis Clinical Investigation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chordate Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chordate Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performance of the PBASE system, in terms of the
      efficacy of treatment in patients with idiopathic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total vasomotor rhinitis symptom score to visit 3</measure>
    <time_frame>From baseline to 28 days after treatment visit 1</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Idiopathic Rhinitis</condition>
  <arm_group>
    <arm_group_label>PBASE system 1.1 + CT100 (active treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PBASE system 1.1 + CT100 (placebo treatment)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PBASE system 1.1 + CT100 (active treatment)</intervention_name>
    <arm_group_label>PBASE system 1.1 + CT100 (active treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PBASE system 1.1 + CT100 (placebo treatment)</intervention_name>
    <arm_group_label>PBASE system 1.1 + CT100 (placebo treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with persistent (&gt;12w) symptoms of idiopathic rhinitis dominated by nasal
             congestion (± secretion) for an average of at least 1 h per day for at least 5 days
             during a period of 14 days

          -  Having nasal congestion as major symptom, and a nasal congestion score of at least 2
             (scale 0-3)

          -  Male or female 18 - 65 years

          -  Judged by the Investigator as suitable for participation in the study without safety
             concerns based on medical history and physical examination.

          -  Willing and able to provide written informed consent prior to participation in the
             clinical investigation

          -  Willing and able to comply with all study related procedures

        Exclusion Criteria:

          -  Patients with Allergic rhinitis, demonstrated by either positive skin prick test,
             phadiatop or RAST

          -  Ongoing respiratory tract infection including nasal cavity at inclusion (treatment
             visit 1)

          -  Systemic steroid treatment less than 4 weeks before the inclusion in the study

          -  Patients with a history of nasal surgery like: septoplasty, cosmetic surgery, conchal
             surgery or any other nasal surgery except closed reposition for nasal fracture

          -  History of frequent nose bleeds or a condition that increases the risk of excessive
             bleeding

          -  Pronounced anterior septal deviation or other significant nasal pathology at
             endoscopic examination

          -  Current malignancy of any kind

          -  Known allergy to polyvinylchloride or medicinal liquid paraffin

          -  Any disease, condition (medical or surgical) which, in the opinion of the
             investigator, might compromise the study results, or would place the subject at
             increased risk.

          -  Any implant with an electrical and/or neurostimulator device, including but not
             limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain
             stimulation, spinal stimulator, bone growth stimulator, or cochlear implant or any
             other implant in the head-, and neck region.

          -  Previous treated with radiation on the face, head or neck regions

          -  Female patients who are pregnant or nursing, or become pregnant at any time from
             inclusion of the study until end of the 8 week follow-up visit

          -  Female patients: unwilling to use adequate contraceptive from the signing of the
             informed consent until end of the 8 week follow-up visit

          -  Received study drug in a clinical trial for an investigational drug within the
             previous 30 days, or 5 half-lives, whichever is longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

